Beijing's Syneron Bio Closes $150M Series B to Scale AI-Powered Macrocyclic Peptide Drug Discovery

Syneron Bio, a Beijing-based peptide drug discovery company specializing in macrocyclic peptides, has closed a $150 million Series B financing round — just four months after raising nearly $100 million in its Series A. The round was co-led by Decheng Capital and CDH VGC, with backing from sovereign wealth investors including Temasek and Abu Dhabi Investment Authority (ADIA). The rapid back-to-back raises signal strong investor confidence in macrocyclic peptides as a therapeutic modality.

Macrocyclic peptides — ring-shaped peptide molecules that combine the high specificity of biologics with favorable oral bioavailability — have emerged as one of the most investable drug modalities in 2026. Syneron's proprietary Synova™ platform uses artificial intelligence and high-throughput screening to design and optimize these molecules across multiple disease areas including oncology, autoimmune conditions, metabolic disease, and rare disorders.

Why the Market Is Watching

The funding comes on the heels of a multibillion-dollar biobucks licensing deal Syneron struck with AstraZeneca in late 2025, validating the commercial potential of its platform. The company is not alone in the space — Unnatural Products raised $45 million in a separate Series B last week, and Pinnacle Medicines closed an $89 million round for oral peptide development in late March.

Together, these deals represent more than $280 million flowing into oral and macrocyclic peptide platforms in just the past month — a pace that would have been unthinkable even two years ago.

What Comes Next

Syneron plans to use the Series B proceeds to advance multiple pipeline programs toward IND-enabling studies and early clinical development. The company's platform has generated candidates with demonstrated oral bioavailability, a critical differentiator in a field where most peptide drugs still require injection.

For the broader peptide therapeutics industry, the Syneron raise underscores a clear trend: investors are betting that the next wave of blockbuster drugs won't just be GLP-1 receptor agonists — they'll be platform-derived peptides engineered by AI for targets that small molecules and antibodies have failed to reach.